Per News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.01.17	So Long DSCI, MRK Seeks New Use For Old Drug, VRX Does It Again, PSTI On Watch (RTTNews)
23.06.16	NYMX Grabs Headlines, MRNS Awaits Data In 2H, PSTI Takes Small Step In DMD Race (RTTNews)
13.01.16	ABBV All Set, PSTI Moving Ahead, Watch Out For ADMS (RTTNews)
12.01.16	Pluristem Gets FDA Nod To Begin Phase I Trial Of PLX-R18 (RTTNews)
31.12.15	FDA Grants Orphan Drug Designation To Pluristem's PLX-PAD Cells (RTTNews)
03.12.15	Pluristem Signs MOU With Fukushima Medical University To Study PLX-R18 In ARS (RTTNews)
17.08.15	Pluristem Gets U.S. Patent For Production Ways And Use Of Placental Cell Therapy (RTTNews)
10.08.15	Pluristem In Talks With Adaptive Pathways Group On Phase II Protocol In CLI (RTTNews)
03.06.15	Pluristem Gets Grant From Israel To Market For PLX Cell Therapy In Japan (RTTNews)
01.12.14	Pluristem Receives Patent In Singapore For 3D Cell Expansion Technology (RTTNews)
06.03.14	Pluristem Therapeutics Says FDA Oks Commercial Scale Cell Manufacturing Process (RTTNews)
21.02.14	BMRN Awaits EMA Nod, KIN Hits A High, Nuvilex Gets Rich, OHRP A Sight Better (RTTNews)
21.01.14	Pluristem's Phase I/II Muscle Injury Trial Meets Primary Endpoints - Quick Facts (RTTNews)
03.10.13	ZLCS Effects Reverse Split, STEM Growing Up, Rockwell Rocks, What's Moving PSTI? (RTTNews)
02.10.13	Pluristem Gets Israel Approval To Begin Phase II Study In IC - Quick Facts (RTTNews)
17.09.13	KYTH Gets A Facelift, PSTI To Resume Study, One Up, Two To Go For NBY (RTTNews)
20.10.09	Pluristem Therapeutics Will Chair a Panel Presentation on Placenta-Derived Adult Stem Cells at the World Conference on Regenerative Medicine (Businesswire)
23.09.09	Pluristem Therapeutics Doses First Patient in U.S. With Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease (Businesswire)
04.08.09	Pluristem’s Award from the Israeli Office of the Chief Scientist Increased to $2.3 Million (Businesswire)
10.06.09	Pluristem Therapeutics to Present at the Second Annual Life Science Conference of The Society of Investment Professionals in Germany (Businesswire)
02.06.09	Stanford’s Professor John Cooke Joins Pluristem’s Scientific Advisory Board (Businesswire)
24.02.09	Pluristem Therapeutics Collaborates with Pharmicell Europe GmbH to Distribute Pluristem’s Cell Therapy Product for Clinical Trials in Germany (Businesswire)
30.01.09	Pluristem Therapeutics Announces US $1,200,000 Restricted Share Purchase (Businesswire)
16.12.08	Pluristem Therapeutics Inc. Announces Filing an IMPD to Commence Clinical Trials Utilizing PLX-PAD for Critical Limb Ischemia in Europe (Businesswire)
11.08.08	Pluristem's PLX-MS Shows Potential Benefit in the Prevention of Multiple Sclerosis (Businesswire)
17.07.08	Pluristem's PLX-BMT Product Featured in the Journal ''Expert Opinion on Biological Therapy'' (Businesswire)
06.05.08	FDA and the Paul Ehrlich Institute (Germany) Approve Pluristem's Regulatory Submissions in Support of a Phase I/II Clinical Trial Utilizing PLX-PAD for Peripheral Artery Disease (Businesswire)
08.01.08	Pluristem Announces Second Clinical Indication Revascularization Effect After PLX-PAD Therapy (Businesswire)
06.11.06	McKesson to Acquire Per-Se Technologies for $1.8 Billion (Businesswire)
06.05.05	Per-Se Technologies to Present at Banc of America Securities Health Ca (Businesswire)
11.04.05	American Hospital Association Selects Per-Se Technologies to Provide R (Businesswire)
05.04.05	Per-Se and DocuSys to Provide Integrated Enterprise Patient Scheduling (Businesswire)
05.04.05	Per-Se's ORSOS One-Call Excels in Recent KLAS Ratings; Strong Custome (Businesswire)
04.04.05	Per-Se Technologies Receives Notification from the Securities and Exch (Businesswire)
09.03.05	Per-Se Technologies Announces 1 Million Share Repurchase Program (Businesswire)
22.02.05	Per-Se Technologies Announces Amendments to Stockholders' Rights Agre (Businesswire)
09.02.05	South Carolina Radiology Group Outsources Revenue Cycle Management to (Businesswire)
01.02.05	Per-Se Technologies to Present at UBS Global Healthcare Services Confe (Businesswire)
18.01.05	Per-Se Technologies Updates Fourth Quarter 2004 Outlook; Earnings Rele (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Per-Se Technologies Inc.

Aktien Top/Flop

Meistgelesene Nachrichten